98%
921
2 minutes
20
Background: Psychometric validation of the Multidimensional Chronic Asthenia Scale (MCAS) was conducted in order to provide an effective tool for assessing the health-related quality of life of French-speaking patients with chronic asthenia (CA).
Methods: Items resulting from the initial formulation of the self-reported MCAS (along with other materials) were completed by French-speaking volunteers with inactive or active inflammatory bowel disease (IBD-I vs. IBD-A) or chronic fatigue syndrome (CFS). Responses from 621 participants (180 patients with IBD-A, 172 with IBD-I, 269 with CFS) collected in a single online survey were divided into three subsamples to test the construct validity of the MCAS (Step 1, N = 240), to confirm its factorial structure (Step 2, N = 204) and to explore its convergent-discriminant validity with the Fatigue Symptoms Inventory (FSI) and revised Piper Fatigue Scale (r-PFS, Step 3, N = 177).
Results: Steps 1 and 2 showed that, as expected, MCAS has four dimensions: feeling of constraint (FoC), physical (PC), life (LC) and interpersonal consequences (IC), which are also related to the duration of CA (i.e., the longer it lasts, the more the dimensions are impacted). The results further showed that the MCAS is sensitive enough to capture between-group differences, with the CFS group being the most impaired, followed by IBD-A and IBD-I. While convergent-discriminant validity between the 4 factors of MCAS and FSI and r-PFS, respectively, was satisfactory overall, Step 3 also pointed to some limitations that call for future research (e.g., shared variances between the PC and IC dimensions of MCAS and behavioral dimension of r-PFS).
Conclusion: Despite these limitations, the MCAS clearly constitutes a promising tool for measuring quantitative differences (i.e., severity/intensity) in CA associated with various diseases, but also, and importantly, the clinically important differences in domains of its expression (i.e., qualitative differences).
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10566142 | PMC |
http://dx.doi.org/10.1186/s40359-023-01358-1 | DOI Listing |
J Endocr Soc
September 2025
Michigan Neuroscience Institute, University of Michigan, Ann Arbor, MI 48109, USA.
Glucocorticoid withdrawal syndrome (GWS) is increasingly recognized as a major barrier to discontinuing chronic glucocorticoid treatment. Despite high rates of adverse effects, 1% to 3% of the population continues long-term glucocorticoid use, in part due to this poorly understood syndrome. Prominent manifestations of GWS include generalized pain, asthenia, and decreased behavioral motivation, which are only reversed by resuming or increasing glucocorticoid use.
View Article and Find Full Text PDFEur J Case Rep Intern Med
July 2025
Department of Internal Medicine, University Hospital of Strasbourg, Strasbourg, France.
Unlabelled: Hypervitaminemia B12, long neglected in clinical practice, is a biological anomaly whose pathological significance remains largely underestimated, particularly in the elderly. While medical attention has historically focused on vitamin B12 deficiency, several recent studies suggest that elevated levels of this vitamin may reveal serious underlying pathologies, such as solid neoplasia, haematological malignancies, chronic liver disease or renal failure. We report the case of a 91-year-old man hospitalized for asthenia, anorexia and altered general condition, in whom vitamin B12 assay revealed major hypervitaminemia (1318 pg/ml).
View Article and Find Full Text PDFCureus
July 2025
Immunohemotherapy Department, Unidade Local de Saúde de São João, Porto, PRT.
Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by arterial, venous, or small-vessel thromboembolic events and/or pregnancy morbidity in the presence of antiphospholipid antibodies. APS can occur in the setting of an underlying systemic autoimmune disease, particularly systemic lupus erythematosus (SLE). SLE is a chronic autoimmune disease that can affect virtually any organ of the body due to the production of antinuclear antibodies.
View Article and Find Full Text PDFFront Med (Lausanne)
July 2025
Department of Internal Medicine and Medical Therapeutics, University of Pavia Medical School, Pavia, Italy.
Bronchiectasis is a chronic and heterogeneous respiratory condition, which is characterized by irreversible abnormal dilatation of the bronchial tree, chronic cough, copious sputum production, and increased risk of acute exacerbations that contribute to the development of chronic respiratory failure, poor exercise tolerance and, consequently, poor quality of life (QoL). A large amount of published data explore regarding the diagnostic approach, the clinical management, and the development of novel therapeutic strategies. Moreover, it is well-known that the exercise-training rehabilitation can be helpful in reducing disease deterioration and relieve symptoms.
View Article and Find Full Text PDFTherap Adv Gastroenterol
July 2025
Department of Social Sciences and Health, Faculty of Medicine, University of Porto, Porto, Portugal.
Background: Liver disease is a leading cause of morbidity and mortality. Patients with end-stage liver disease (ESLD) experience multiple physical symptoms. Despite the poor prognosis and significant symptom burden, palliative care integration remains limited.
View Article and Find Full Text PDF